Tesamorelin

Description

Tesamorelin – Advanced GHRH Analogue Research Peptide

Buy Tesamorelin in Canada – High-Purity Standard for Somatotropic & Lipolytic Signaling Research

Tesamorelin is a third-generation synthetic growth hormone-releasing factor analogue engineered with an N-terminal hexenoyl modification that provides resistance to dipeptidyl peptidase-4 (DPP-4) degradation. By binding selectively to pituitary GHRH receptors, Tesamorelin stimulates the natural, physiologically regulated pulsatile secretion of endogenous growth hormone without causing severe tachyphylaxis or disrupting negative feedback loops. For Canadian academic institutions and analytical facilities evaluating visceral adiposity, lipid remodeling pathways, and somatotropic axis kinetics, North Vital Labs provides analytical-grade Tesamorelin backed by independent third-party verification.

Primary Research Applications

• Pulsatile Somatotropin Secretion: Serves as a primary reference standard for measuring pituitary GHRH receptor affinity and physiological growth hormone release dynamics.

• Visceral Adipose Tissue (VAT) Lipolysis: Facilitates the analysis of localized abdominal adipocyte reduction, free fatty acid mobilization, and targeted lipid catabolism.

• Hepatic IGF-1 Axis Modulation: Evaluates downstream circulating insulin-like growth factor 1 (IGF-1) transcription rates and cellular metabolic homeostasis.

• Cardiometabolic & Lipid Profile Markers: Enables controlled laboratory observation of triglyceride kinetics, non-HDL lipid balance, and hepatic fat accumulation models.

Why Canadian Researchers Choose North Vital Labs

• 100% Domestic Canadian Fulfillment: Shipments originate directly within Canada, guaranteeing no border seizures, import tariffs, or international customs clearance delays.

• HPLC Lab-Verified Purity: Each lot undergoes independent analytical testing to ensure 99%+ chemical purity, complete with accessible Certificates of Analysis (COAsTesamorelin (brand name Egrifta SV) is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH). It consists of 44 amino acids and is engineered with a hexenoyl moiety to increase its stability and half-life compared to natural GHRH.

Primary Medical Use

• Indication: Approved by the FDA specifically to reduce excess abdominal fat (visceral adipose tissue) in adults with HIV-associated lipodystrophy.

• Mechanism: It binds to GHRH receptors on pituitary somatotropes, stimulating the endogenous production and pulsatile release of Growth Hormone (GH). GH then acts on the liver to stimulate Insulin-like Growth Factor 1 (IGF-1) production and directly promotes lipolysis—particularly in metabolically active visceral fat.

• Selectivity: Unlike exogenous human growth hormone (rhGH), Tesamorelin preserves the pituitary gland’s natural negative feedback loop (via somatostatin), significantly reducing the risk of supraphysiologic GH spikes.

Common Off-Label / Wellness Contexts

• Body Composition & Fat Loss: Frequently sought in longevity and bodybuilding circles for visceral fat reduction and preservation of lean mass.

• Cognitive Function: Clinical studies have evaluated Tesamorelin’s potential benefits on cognitive performance and brain amyloid levels in older adults with mild cognitive impairment.

Administration & Storage

• Route: Subcutaneous injection, typically administered once daily into the abdomen.

• Preparation: Lyophilized powder reconstituted with sterile water prior to injection. Reconstituted vials generally require refrigeration.

Potential Side Effects & Risks

• Common: Injection-site reactions (erythema, itching, swelling), arthralgia, myalgia, peripheral edema, and paresthesia.

• Glucose Metabolism: Can elevate blood glucose levels and impair insulin sensitivity; patients require periodic monitoring of fasting glucose and HbA1c.

• IGF-1 Elevation: Sustained high levels of IGF-1 warrant monitoring, particularly due to theoretical risks concerning cell proliferation and oncogenesis.

• Contraindications: Active malignancy, pregnancy, known hypersensitivity to GHRH analogs, or pituitary disruption/hypopituitarism.